Selected Quarterly Financial Data (Unaudited)

12 Months Ended

Jun. 30, 2020

15. Selected Quarterly Financial Data (Unaudited)

The following is selected quarterly financial data for fiscal 2020 and 2019. The sum of the quarters may not equal year-to-date due to rounding.



(in millions, except per common share amounts)	First Quarter (1)			Second Quarter		Third Quarter			Fourth Quarter (2)
Fiscal 2020
Revenue	$	37,341		$	39,735	$	39,157		$	36,689
Gross margin	1,679			1,714		1,885			1,590
Distribution, selling, general and administrative expenses	1,107			1,163		1,165			1,137
Net earnings/(loss)	(4,921		)	220		351			657
Less: Net earnings attributable to noncontrolling interests	(1		)	—		(1		)	(1		)
Net earnings/(loss) attributable to Cardinal Health, Inc.	(4,922		)	220		350			656

Net earnings/(loss) attributable to Cardinal Health, Inc. per common share:
Basic	$	(16.65	)	$	0.75	$	1.20		$	2.25
Diluted	(16.65		)	0.75		1.19			2.23


(1)	Includes a $5.63 billion pre-tax charge for the opioid litigation ($5.14 billion after tax).


(2)	Includes a $579 million pre-tax gain ($493 million after tax) in connection with the sale of our remaining equity interest in a partnership that owned naviHealth.



(in millions, except per common share amounts)	First Quarter (1)			Second Quarter			Third Quarter		Fourth Quarter
Fiscal 2019
Revenue	$	35,213		$	37,740		$	35,228	$	37,353
Gross margin	1,667			1,730			1,764		1,674
Distribution, selling, general and administrative expenses	1,155			1,064			1,097		1,168
Net earnings/(loss)	594			281			296		194
Less: Net earnings attributable to noncontrolling interests	(1		)	(1		)	—		—
Net earnings/(loss) attributable to Cardinal Health, Inc.	593			280			296		194

Net earnings/(loss) attributable to Cardinal Health, Inc. per common share:
Basic	$	1.95		$	0.94		$	0.99	$	0.65
Diluted (3)	1.94			0.93			0.99		0.65

(1)

Includes a $508 million gain ($378 million after tax) related to the naviHealth divestiture.